AstraZeneca is set to unveil landmark data from four major pivotal trials at the upcoming European Society for Medical Oncology (ESMO) Congress 2025, taking place from October 17–21.

The presentations reinforce the company’s commitment to transforming cancer treatment through its industry-leading oncology portfolio and robust pipeline.

The new data highlight the potential of AstraZeneca’s innovative therapies to improve outcomes across multiple cancer types, including early and advanced breast, bladder, and gastric cancers. Among more than 95 abstracts, AstraZeneca will feature nine approved and nine potential new medicines, with two late-breaking presentations in Presidential Symposia and 26 oral sessions.

Two key Presidential Symposium presentations will showcase results from the DESTINY-Breast11 and DESTINY-Breast05 Phase III trials, underscoring the potential of Enhertu (trastuzumab deruxtecan) in patients with HER2-positive early breast cancer. Meanwhile, new data from the TROPION-Breast02 trial will demonstrate the promise of Datroway (datopotamab deruxtecan) as a first-line treatment for metastatic triple-negative breast cancer (TNBC)—one of the most aggressive forms of breast cancer.

Further advancing its immunotherapy strategy, AstraZeneca will present results from the POTOMAC and MATTERHORN Phase III trials of Imfinzi (durvalumab). The POTOMAC study explores Imfinzi’s role alongside standard-of-care BCG therapy in high-risk non-muscle-invasive bladder cancer (NMIBC), while the MATTERHORN trial delivers final overall survival outcomes for Imfinzi combined with FLOT chemotherapy in resectable, early-stage and locally advanced gastric and gastroesophageal junction (GEJ) cancers.

Dr. Susan Galbraith, Executive Vice President, Oncology R&D, AstraZeneca, said: “We are advancing a broad portfolio of new treatments that have the potential to transform patient care, particularly in breast cancer. At ESMO 2025, we’re sharing pivotal data from DESTINY-Breast11, DESTINY-Breast05, and TROPION-Breast02, along with emerging results from our next generation of oncology medicines, including saruparib in prostate cancer, torvu-sam in ovarian cancer, and rilvegostomig in non-small cell lung cancer.”

Dave Fredrickson, Executive Vice President, Oncology Business Unit, AstraZeneca, added: “The strength and momentum of our oncology pipeline are on full display at this year’s ESMO Congress. Beyond our advancements in breast cancer with Enhertu and Datroway, the results from POTOMAC highlight the growing benefits of immunotherapy in early-stage bladder cancer. These findings underscore our strategy to deliver transformative treatments earlier in the disease pathway, where they can make the greatest difference for patients.”